Donate

New Data Supports Safety & Efficacy of ELOCTATE

August 11, 2015

Note: This is an edited version of a press release from Biogen. To read the original release, click here. _____________________________________ Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] experienced low bleeding rates, Biogen and Swedish Orphan Biovitrum AB (Sobi) announced on Monday, August 10, […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.